Zinbryta, Nuplazid (FDA APPROVED DRUGS) Neurology

Powered by WP Review

Zinbryta (daclizumab),it is an FDA approved drug, approved in may 2016.

Information about zinbryta:

It is an interleukin-2 receptor blocking humanized monoclonal antibody.

It is specifically indicated treatment of adult patients with multiple sclerosis. The treatment pattern should be reserved for the patients who have an inadequate response to two or more drugs indicated for the treatment of multiple sclerosis. It can be used as the exactly how the doctor has prescribed, directions written on the prescription label should be followed by the patient. It is not to be used in small or large doses and also no longer than prescribed.

It is supplied as a solution for the subcutaneous injection. The recommended dose is 150milligrams injected subcutaneously once in a month. Please see the drug label for the specific administration instructions.

Zinbryta Contraindications:

It is not to be used in the patients with hepatic disease or hepatic impairment, a history of an autoimmune condition involving the liver, or the history of hypersensitivity to daclizumab or any other drugs.

Hepatic injury:

This drug can cause severe liver injury and sometimes life-threatening events, liver failure and autoimmune hepatitis.

Acute hypersensitivity:

It can cause anaphylaxis, angioedema, and urticaria after certain doses. Discontinue if the symptoms like above have shown in the patient.

Depression and suicide:

It can cause depression disorders,  advise patients and caregivers to observe the symptoms if they are worsening, immediately call the doctor, in case severe symptoms discontinue the drug.

Zinbryta Side effects:

Adverse effects associated with the use of this drugs are

  • Influenza
  • Rash
  • Nasopharyngitis
  • Dermatitis
  • Bronchitis
  • Oropharyngeal pain
  • Eczema
  • Lymphadenopathy
  • Upper respiratory tract infection

Mechanism of action:

It is an interleukin-2 receptor blocking humanized monoclonal antibody.

It can involve modulation of IL-2 mediated activation of lymphocytes through binding to CD25 and a subunit of the high-affinity IL-2 receptor.

 

Nuplazid (pimavanserin)

it is an FDA approved drug, approved in may 2016.

Information about nuplazid:

It can exert its effect by the combination of inverse agonist and antagonist activity at serotonin 5-HT2A receptors and to a lesser extent at serotonin 5-HT2C receptors.

It is mainly used for the treatment of  hallucinations and delusions associated with Parkinson’s disease.

It is supplied as a tablet for oral administration. The recommended dose of this drug is 34mg, taken orally as two 17mg strength tablets once daily.

Nuplazid Side effects:

Adverse effects associated with this drug are as follows

  • Confusional state
  • Peripheral state

It comes in a black box because it can sometimes cause a death of a person. It is not approved for the treatment of patients with dementia-related psychosis unrelated to the hallucinations and delusions related to the Parkinson’s disease.

Mechanism of action:

The main actions of this drug are to treat hallucinations and delusions associated with the Parkinson’s disease.

FDA APPROVED DRUGS 

Leave a Reply